Richard Hoglund
Head of Pharmacometrics
Clinical Pharmacology
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
Recent publications
Development of a Disease-Specific Virtual Malaria Population for Physiologically-Based Pharmacokinetic Modeling.
Journal article
Ding J. et al, (2026), CPT Pharmacometrics Syst Pharmacol, 15
Pharmacometric evaluation of pre-referral rectal artesunate in children with severe malaria.
Journal article
Adehin A. et al, (2026), Br J Clin Pharmacol
A dynamic pharmacometric framework defining the relationship between ivermectin exposure and mosquito lethality.
Journal article
Hoglund RM. et al, (2026), Sci Rep
Population Pharmacokinetics and Pharmacodynamics of Paracetamol in Malaysian Patients With Plasmodium knowlesi Malaria.
Journal article
Wattanakul T. et al, (2026), CPT Pharmacometrics Syst Pharmacol, 15
Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria.
Journal article
Ding J. et al, (2026), Br J Clin Pharmacol, 92, 589 - 605
